

INTRODUCING ^{PR} DYSPORT THERAPEUTIC™ (abobotulinumtoxinA for injection)



Now available in Canada for the treatment of cervical dystonia and adult upper limb spasticity

DYSPORT THERAPEUTIC IS INDICATED:

- To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults
- For the symptomatic treatment of focal spasticity affecting the upper limbs in adults

ORDERING INFORMATION:

| Strength and dosage form | DIN | UPC |
|-------------------------------------------------------------------|----------|--------------|
| 500 U vial, sterile lyophilized powder for solution for injection | 02456117 | 191161600014 |
| 300 U vial, sterile lyophilized powder for solution for injection | 02460203 | 191161600007 |

DYSPORT THERAPEUTIC will be available to order through Accuristix and Canadian Pharmaceutical Distribution Network (CPDN)

Accuristix contact

csr@ipSen.com
Phone: 866-332-2301
Fax: 800-786-1967

CPDN contact

cpdnprogramhelp@lynden.com

East region

Phone: 866-322-2736
Fax: 877-322-0286

West region

Phone: 866-895-2736
Fax: 877-895-0286

FOR CERVICAL DYSTONIA IN ADULTS:

- **Initial dose: 500 U** given intramuscularly as a divided dose among affected muscles
- **Repeat dose, if needed:** In uncontrolled open-label clinical trials, doses were in the range **between 250 U and 1000 U***

FOR UPPER LIMB SPASTICITY IN ADULTS:

- In the pivotal trial, **doses of 500 U and 1000 U** were divided among selected muscles at a given treatment session
- Dosing in initial and sequential treatment sessions should be tailored based on the size, number and location of muscles involved, severity of spasticity, presence of local muscle weakness, patient's response to previous treatment and/or adverse event history with DYSPORT THERAPEUTIC*

Re-treatment, if needed, should not occur in intervals of less than 12 weeks

*Please see the Product Monograph for complete dosing and administration instructions.

Store at 2 to 8°C. Protect from light. Do not freeze after reconstitution.

Administer within 24 hours of reconstitution

Please consult the product monograph at http://ipSen.ca/wp-content/uploads/2017/01/Dysport-therapeutic-pm-Jan-3_17.pdf for important information relating to contraindications, warnings, precautions, conditions of clinical use, adverse reactions, drug interactions and dosing. The Product Monograph is also available by calling Ipsen Medical Information at 1-855-215-2288.

Reference: DYSPORT THERAPEUTIC Product Monograph. DYSPORT THERAPEUTIC is a trademark of IPSEN BIOPHARM LTD. © 2017 Ipsen BioPharmaceuticals. All rights reserved.

